We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+5.62%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.2B
AUM Growth
+$36.4M
Cap. Flow
+$49.6M
Cap. Flow %
2.25%
Top 10 Hldgs %
26.49%
Holding
159
New
12
Increased
46
Reduced
21
Closed
14

Top Buys

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$23.1M
2
SYK icon
Stryker
SYK
+$19.3M
3
HOLX
Hologic
HOLX
+$13.4M
4
ZBH icon
Zimmer Biomet
ZBH
+$11.4M
5
MOH icon
Molina Healthcare
MOH
+$10.4M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$27.5M
2
DHR icon
Danaher
DHR
+$19.3M
3
MDT icon
Medtronic
MDT
+$19.2M
4
BCR
CR Bard Inc.
BCR
+$18.4M
5
WCG
Wellcare Health Plans, Inc.
WCG
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85.16%
2 Financials 2.8%
3 Consumer Discretionary 0.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INGN icon
76
Inogen
INGN
$164M
$9.53M 0.43%
+80,000
New +$8.81M
FPRX
77
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$9.32M 0.42%
425,000
+207,300
+95% +$6.67M
HQY icon
78
HealthEquity
HQY
$8.75B
$9.1M 0.41%
195,000
+30,000
+18% +$1.49M
ZGNX
79
DELISTED
Zogenix, Inc.
ZGNX
$9.03M 0.41%
225,500
+125,500
+126% +$4.82M
CO
80
DELISTED
Global Cord Blood Corporation
CO
$8.76M 0.4%
880,000
– –
TVTX icon
81
Travere Therapeutics
TVTX
$5.78B
$8.43M 0.38%
400,000
– –
OBSV
82
DELISTED
ObsEva SA Ordinary Shares
OBSV
$8.2M 0.37%
840,000
– –
AFAM
83
DELISTED
Almost Family Inc
AFAM
$8.17M 0.37%
147,540
-214,460
-59% -$11.4M
PRTK
84
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$8.05M 0.37%
450,000
– –
BLUE
85
DELISTED
bluebird bio
BLUE
$8.02M 0.36%
3,474
+772
+29% +$1.57M
SRGA
86
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$8M 0.36%
65,000
– –
RARE icon
87
Ultragenyx Pharmaceutical
RARE
$2.55B
$7.56M 0.34%
163,000
– –
SAGE
88
DELISTED
Sage Therapeutics
SAGE
$7.41M 0.34%
45,000
+12,500
+38% +$1.21M
ARNA
89
DELISTED
Arena Pharmaceuticals Inc
ARNA
$7.3M 0.33%
215,000
– –
TXMD icon
90
TherapeuticsMD
TXMD
$24M
$7.1M 0.32%
23,500
-8,500
-27% -$2.37M
SGEN
91
DELISTED
Seagen Inc. Common Stock
SGEN
$6.69M 0.3%
125,000
– –
BHVN
92
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$6.58M 0.3%
244,000
– –
CMTA
93
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$6.55M 0.3%
345,000
– –
CLSD
94
DELISTED
Clearside Biomedical
CLSD
$6.54M 0.3%
62,333
– –
ACHN
95
DELISTED
Achillion Pharmaceuticals
ACHN
$6.48M 0.29%
2,250,000
+118,600
+6% +$431K
STE icon
96
Steris
STE
$23.1B
$6.47M 0.29%
74,000
– –
ZLAB icon
97
Zai Lab
ZLAB
$2.62B
$6.26M 0.28%
295,000
-17,500
-6% -$465K
ABLX
98
DELISTED
Ablynx NV
ABLX
$6.25M 0.28%
+250,000
New +$5.65M
SPRO icon
99
Spero Therapeutics
SPRO
$73M
$6.17M 0.28%
+525,000
New +$6.44M
TTPH
100
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$5.99M 0.27%
47,500
– –
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Rock Springs Capital Management held 159 positions worth $2.2B, up 1.7% from $2.17B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rock Springs Capital Management's Q4 2017 filing shows 12 new, 46 increased, 21 reduced and 14 closed positions. Its largest new stake was Teleflex: 91,750 shares worth $22.8M. The largest sale was Aetna Inc, an estimated $27.5M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 80% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q4 2017 buy was Teleflex: 91,750 shares worth $22.8M.
  • Rock Springs Capital Management added most to Zimmer Biomet in Q4 2017, an estimated $11.4M increase.
  • Rock Springs Capital Management's biggest Q4 2017 reduction was Aetna Inc, cutting an estimated $27.5M.
  • Rock Springs Capital Management fully exited Danaher in Q4 2017, selling an estimated $19.3M.
  • Rock Springs Capital Management's ten largest holdings make up 26% of its $2.2B portfolio in Q4 2017.
  • Rock Springs Capital Management opened 12 new positions and closed 14 in Q4 2017.
  • Rock Springs Capital Management's portfolio value rose 1.7% quarter-over-quarter to $2.2B.

Based on Rock Springs Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.